Evidence map›Paper›PMID 31291250›Full record

Observational studyPloS one2019

Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study.

Delphine Héquet, Cyrille Huchon, Anne-Laure Soilly, Bernard Asselain, Helene Berseneff, Caroline Trichot, Aline Combes, Karine Alves, Thuy Nguyen, Roman Rouzier and 1 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Prosigna test in breast cancer: real-life experience.Breast cancer research and treatment · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Delphine HéquetDepartment of Surgical Oncology, Institut Curie, St Cloud, France.ORCID 0000-0001-8926-5651
Cyrille HuchonDepartment of Gynecology, Poissy-St Germain hospital, Poissy, France.
Anne-Laure SoillyHealth Economics Department, CHU Dijon Bourgogne, Délégation à la Recherche Clinique et à l'Innovation, USMR, Dijon, France.
Bernard AsselainDepartment of Biostatistics, Institut Curie, Paris, France.
Helene BerseneffDepartment of Gynecology, René Dubos Hospital, Pontoise, France.
Caroline TrichotDepartment of Gynecology, Antoine Béclère Hospital, Clamart, France.
Aline CombesDepartment of Gynecology, André Mignot Hospital, Versailles, France.
Karine AlvesDepartment of Gynecology, Argenteuil Hospital, Argenteuil, France.
Thuy NguyenDepartment of Gynecology, Louis Mourier Hospital, Colombes, France.
Roman RouzierDepartment of Surgical Oncology, Institut Curie, St Cloud, France.
Sandrine BaffertHealth Economics Department, Institut Curie, Paris, France/CEMKA-EVAL, Bourg-La-Reine, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe organization of health care for breast cancer (BC) constitutes a public health challenge to ensure quality of care, while also controlling expenditure. Few studies have assessed the global care pathway of early BC patients, including a description of direct medical costs and their determinants. The aims of this multicenter prospective study were to describe care pathways of BC patients in a geographic territory and to calculate the global direct costs of early stage BC during the first year following diagnosis.

methodsOPTISOINS01 was a multicenter, prospective, observational study including early BC patients from diagnosis to one-year follow-up. Direct medical costs (in-hospital and out-of-hospital costs, supportive care costs) and direct non-medical costs (transportation and sick leave costs) were calculated by using a cost-of-illness analysis based on a bottom-up approach. Resources consumed were recorded in situ for each patient, using a prospective direct observation method.

resultsData from 604 patients were analyzed. Median direct medical costs of 1 year of management after diagnosis in operable BC patients were €12,250. Factors independently associated with higher direct medical costs were: diagnosis on the basis of clinical signs, invasive cancer, lymph node involvement and conventional hospitalization for surgery. Median sick leave costs were €8,841 per patient and per year. Chemotherapy was an independent determinant of sick leave costs (€3,687/patient/year without chemotherapy versus €10,706 with chemotherapy). Forty percent (n = 242) of patients declared additional personal expenditure of €614/patient/year. No drivers of these costs were identified.

conclusionInitial stage of disease and the treatments administered were the main drivers of direct medical costs. Direct non-medical costs essentially consisted of sick leave costs, accounting for one-half of direct medical costs for working patients. Out-of-pocket expenditure had a limited impact on the household.

Indexed as

Health Care CostsAdultAgedAged, 80 and overBreast NeoplasmsCost of IllnessCritical PathwaysFemaleFranceHospital CostsHumansMiddle AgedNational Health ProgramsProspective Studies

Identifiers

PMID31291250
PMCPMC6619952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.